Tags: The University of Sydney, Australia, Healthcare & Lifesciences
Stimulating β3 adrenoreceptors enhances blood flow and tissue healing. A topical lipogel effectively delivers Mirabegron, a β3AR agonist, promoting wound recovery. With a method-of-use patent, this approach targets conditions like diabetic foot ulcers, scleroderma, pressure sores, and peripheral arterial disease. The technology aims to fill a gap in diabetic ulcer treatments that include wound dressing or amputation. Current treatments lack pharmacological options to improve healing.
IP Type or Form Factor: Patent Pending; Process & Method; Material
TRL: 5 - prototype ready for testing in intended environment
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
![Chronic Wound Healing Using β3AR Agonists](https://substackcdn.com/image/fetch/w_720,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd7230656-a9c0-4569-b4fe-9a58d37f1e82_1024x1024.jpeg)
![Chronic Wound Healing Using β3AR Agonists](https://substackcdn.com/image/fetch/w_720,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9ecf2a49-7762-4ffd-ae0b-0b65be6f24e7_363x356.png)